<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">geriatr</journal-id><journal-title-group><journal-title xml:lang="ru">Российский журнал гериатрической медицины</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Geriatric Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2686-8636</issn><issn pub-type="epub">2686-8709</issn><publisher><publisher-name>Сайт издателя</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37586/2686-8636-4-2025-468-478</article-id><article-id custom-type="elpub" pub-id-type="custom">geriatr-603</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Прогностическое значение эритропоэтина у пациентов пожилого и старческого возраста с хронической сердечной недостаточностью и анемией</article-title><trans-title-group xml:lang="en"><trans-title>Prognostic value of erythropoietin in elderly and senile patients with heart failure and anemia</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5231-371X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дементьева</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Dementeva</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Дементьева Анна Викторовна</p><p>Москва</p></bio><bio xml:lang="en"><p>Dementyeva Anna Viktorovna</p><p>Moscow</p><p> </p></bio><email xlink:type="simple">AnnaD283@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4004-7802</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Соломахина</surname><given-names>Н. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Solomakhina</surname><given-names>N. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ГБУЗ «Госпиталь для ветеранов войн № 1 Департамента здравоохранения г. Москвы»<country>Россия</country></aff><aff xml:lang="en">Veterans Affairs Hospital 1<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">ФГАОУ ВО Первый МГМУ им. И. М. Сеченова Минздрава России (Сеченовский&#13;
Университет)<country>Россия</country></aff><aff xml:lang="en">Department of Hospital-based Therapy, I. M. Sechenov First Moscow State Medical University (Sechenov University), Sklifosovsky Institute for Clinical Medicine<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>14</day><month>12</month><year>2025</year></pub-date><volume>0</volume><issue>4</issue><fpage>468</fpage><lpage>478</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Дементьева А.В., Соломахина Н.И., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Дементьева А.В., Соломахина Н.И.</copyright-holder><copyright-holder xml:lang="en">Dementeva A.V., Solomakhina N.I.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.geriatr-news.com/jour/article/view/603">https://www.geriatr-news.com/jour/article/view/603</self-uri><abstract><sec><title>ЦЕЛЬ</title><p>ЦЕЛЬ: изучить прогностическое значение уровней эритропоэтина (ЭПО) у пациентов пожилого и старческого возраста с хронической сердечной недостаточностью (ХСН) и анемией.</p></sec><sec><title>МАТЕРИАЛЫ И МЕТОДЫ</title><p>МАТЕРИАЛЫ И МЕТОДЫ. У 105 пациентов с ХСН и анемией в возрасте от 65 до 90 лет однократно определяли в сыворотке крови уровни ЭПО. Период наблюдения составил 24 мес. Первичной конечной точкой была смерть от всех причин. Адекватность выработки эндогенного ЭПО оценивали по соотношению «наблюдаемый ЭПО / прогнозируемый ЭПО» (О/Р), рассчитанному на основании уровней ЭПО и гемоглобина у 10 пациентов контрольной группы с железодефицитной анемией без ХСН [отношение рисков (HR) 1,004 ± 0,004 [95 % доверительный интервал (CI); (0,919–1,080)]. Значение О/Р &lt; 0,9 считали недостаточной выработкой ЭПО, О/Р &gt; 1,1 – избыточной, О/Р = 1,0 – адекватной. Метод Каплана – Мейера использовали для сравнения выживаемости в зависимости от значения О/Р уровней ЭПО. Регрессионный анализ пропорциональных рисков Кокса использовали для оценки влияния значения О/Р уровней ЭПО на риск смерти.</p></sec><sec><title>РЕЗУЛЬТАТЫ</title><p>РЕЗУЛЬТАТЫ. У пациентов с ХСН и анемией средний уровень ЭПО составил (35,900 ± 2,537) мМЕ/мл [8,46; 154,00]. Согласно полученному соотношению О/Р уровней ЭПО, у 59 % пациентов выявлены признаки избыточной выработки ЭПО (О/Р &gt; 1,1), у 18 % – недостаточной выработки (О/Р &lt; 0,9) и адекватной – у 23 % (О/Р = 1,0). Метод Каплана – Мейера показал значимо более высокую смертность у пациентов с О/Р &gt; 1,1, чем у пациентов с О/Р &lt; 0,9 и О/Р = 1,0 (р = 0,00418). Анализ пропорциональных рисков Кокса выявил влияние соотношения О/Р &gt; 1,1 на риск смерти на уровне тенденции в однофакторном анализе [HR 0,947 (95 % CI; 0,893–1,004), р = 0,069] и значимое – в многофакторном [HR 0,924 (95 % CI; 0,859–0,994), р = 0,034].</p></sec><sec><title>ЗАКЛЮЧЕНИЕ</title><p>ЗАКЛЮЧЕНИЕ. Для пациентов пожилого и старческого возраста с ХСН и анемией характерна выраженная вариабельность уровней ЭПО, при этом может быть избыточная, недостаточная или адекватная выработка ЭПО. Выявлено прогностическое значение О/Р уровней ЭПО как маркера несоответствия между степенью анемии и реальной выработкой ЭПО, при этом значение О/Р &gt; 1,1 свидетельствует о неблагоприятном прогнозе, т. к. коррелирует с повышенным риском смерти.</p></sec></abstract><trans-abstract xml:lang="en"><p>Prognostic value of erythropoietin in elderly and senile patients with heart failure and anemia</p><sec><title>OBJECTIVE</title><p>OBJECTIVE: to study the prognostic value of erythropoietin (EPO) levels in elderly and senile patients with chronic heart failure (CHF) and anemia.</p></sec><sec><title>MATERIAL AND METHODS</title><p>MATERIAL AND METHODS. EPO levels in blood serum were determined once in 105 patients with CHF and anemia aged 65 to 90 years. The follow-up period was 24 months. The primary endpoint was death from all causes. The adequacy of endogenous EPO production was assessed by the ratio «observed EPO / predicted EPO» (O/P), calculated on the basis of EPO and hemoglobin levels in patients of the control group with iron deficiency anemia without CHF – [HR 1.004 ± 0.004 [95 % CI; (0.919–1.080)]. The value of O/P &lt; 0.9 was considered insufficient production of EPO, O/P &gt; 1.1 – excessive, O/P = 1.0 – adequate. The Kaplan – Meyer method was used to compare survival rates depending on the value of O/P levels of EPO. Regression analysis of proportional hazards of Cox was used to assess the effect of the value of O/P levels of EPO on the risk of death.</p></sec><sec><title>RESULTS</title><p>RESULTS. In patients with CHF and anemia, the average EPO level was (35.900 ± 2.537) mIU/ml [8.46; 154.00]. According to the obtained ratio of O/P levels of EPO, 59 % of patients showed signs of excessive production of EPO (O/P &gt; 1.1), 18 % – insufficient production (O/P &lt; 0.9) and adequate – in 23 % (O/P = 1.0). The Kaplan – Mayer method showed significantly higher mortality in patients with O/P &gt; 1.1 than in patients with O/P &lt; 0.9  and O/P = 1 (p = 0.00418). The analysis of proportional hazards of Cox revealed an effect on the risk of death of the ratio O/P &gt; 1.1 at the trend level in a single-factor analysis [HR 0.947 (95 % CI; 0.893–1.004), p = 0.069] and significant in a multifactorial [HR 0.924 (95 % CI; 0.859–0.994), p = 0.034].</p></sec><sec><title>CONCLUSION</title><p>CONCLUSION. Elderly and senile patients with CHF and anemia are characterized by marked variability in EPO levels, while there may be excessive, insufficient or adequate EPO production. The prognostic value of O/P levels of EPO as a marker of the discrepancy between the degree of anemia and the actual production of EPO was revealed, while the O/P value &gt;1.1 indicates an unfavorable prognosis, since it correlates with an increased risk of death.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>пожилой и старческий возраст</kwd><kwd>хроническая сердечная недостаточность</kwd><kwd>анемия</kwd><kwd>эритропоэтин</kwd><kwd>прогноз</kwd></kwd-group><kwd-group xml:lang="en"><kwd>elderly and senile age</kwd><kwd>chronic heart failure</kwd><kwd>anemia</kwd><kwd>erythropoietin</kwd><kwd>prognosis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Фомин И. В. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. // Российский кардиологический журнал. — 2016. — № 8. — С. 7–13.</mixed-citation><mixed-citation xml:lang="en">Fomin I. V. Chronic heart failure in Russian Federation: what do we know and what to do. Russian journal of cardiology. 2016 ; (8) : 7–13. (In Russ.). doi: 10.15829/1560-4071-2016-8-7-13.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Beguin Y., Clemons G. K., Pootrakul P., et al. Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood. 1993 ; 81 (4) : 1067–1076.</mixed-citation><mixed-citation xml:lang="en">Beguin Y., Clemons G. K., Pootrakul P., et al. Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood. 1993 ; 81 (4) : 1067–1076.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Spivak J. L. Serum immunoreactive erythropoietin in health and disease. J Perinat Med. 1995 ; 23 (1–2) : 13–17. doi: 10.1515/jpme.1995.23.1-2.13.</mixed-citation><mixed-citation xml:lang="en">Spivak J. L. Serum immunoreactive erythropoietin in health and disease. J Perinat Med. 1995 ; 23 (1–2) : 13–17. doi: 10.1515/jpme.1995.23.1-2.13.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">van der Meer P., Lok D. J., Januzzi J. L., et al. Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. Eur Heart J. 2008 ; 29 (12) : 1510–1515. doi: 10.1093/eurheartj/ehn205.</mixed-citation><mixed-citation xml:lang="en">van der Meer P., Lok D. J., Januzzi J. L., et al. Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. Eur Heart J. 2008 ; 29 (12) : 1510–1515. doi: 10.1093/eurheartj/ehn205.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Grote Beverborg N., van der Wal H. H., Klip I. T., et al. High serum erythropoietin levels are related to heart failure development in subjects from the general population with albuminuria: data from PREVEND. Eur J Heart Fail. 2016 ; 18 (7) : 814–821. doi: 10.1002/ejhf.484.</mixed-citation><mixed-citation xml:lang="en">Grote Beverborg N., van der Wal H. H., Klip I. T., et al. High serum erythropoietin levels are related to heart failure development in subjects from the general population with albuminuria: data from PREVEND. Eur J Heart Fail. 2016 ; 18 (7) : 814–821. doi: 10.1002/ejhf.484.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Garimella P. S., Katz R., Patel K. V., et al. Health ABC study. Association of serum erythropoietin with cardiovascular events, kidney function decline, and mortality: the health aging and body composition study. Circ Heart Fail. 2016 ; 9 (1) : e002124. doi: 10.1161/CIRCHEARTFAILURE.115.002124.</mixed-citation><mixed-citation xml:lang="en">Garimella P. S., Katz R., Patel K. V., et al. Health ABC study. Association of serum erythropoietin with cardiovascular events, kidney function decline, and mortality: the health aging and body composition study. Circ Heart Fail. 2016 ; 9 (1) : e002124. doi: 10.1161/CIRCHEARTFAILURE.115.002124.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Nagai T., Nishimura K., Honma T., et al. Prognostic significance of endogenous erythropoietin in longterm outcome of patients with acute decompensated heart failure. Eur J Heart Fail. 2016 ; 18 (7) : 803–813. doi: 10.1002/ejhf.537.</mixed-citation><mixed-citation xml:lang="en">Nagai T., Nishimura K., Honma T., et al. Prognostic significance of endogenous erythropoietin in longterm outcome of patients with acute decompensated heart failure. Eur J Heart Fail. 2016 ; 18 (7) : 803–813. doi: 10.1002/ejhf.537.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Tkaczyszyn M., Comín-Colet J., Voors A. A., et al. Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patients. Eur J Heart Fail. 2021 ; 23 (10) : 1677–1686. doi: 10.1002/ejhf.2253.</mixed-citation><mixed-citation xml:lang="en">Tkaczyszyn M., Comín-Colet J., Voors A. A., et al. Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patients. Eur J Heart Fail. 2021 ; 23 (10) : 1677–1686. doi: 10.1002/ejhf.2253.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Montero D., Haider T., Flammer A. J. Erythropoietin response to anaemia in heart failure. Eur J Prev Cardiol. 2019 ; 26 (1) : 7–17. doi: 10.1177/2047487318790823.</mixed-citation><mixed-citation xml:lang="en">Montero D., Haider T., Flammer A. J. Erythropoietin response to anaemia in heart failure. Eur J Prev Cardiol. 2019 ; 26 (1) : 7–17. doi: 10.1177/2047487318790823.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ефремова Е. В., Шутов А. М., Подусов А. С. Прогностическое значение эндогенного эритропоэтина при хронической сердечной недостаточности // Нефрология и диализ. — 2021. — Т. 23, № 1. — С. 90–97.</mixed-citation><mixed-citation xml:lang="en">Efremova E. V., Shutov A. M., Podusov A. S. The prognostic value of endogenous erythropoietin in chronic heart failure. Nephrology and Dialysis. 2021;23(1):90-97. (In Russ.)]. doi: 10.28996/2618-9801-2021-1-90-97.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Chatterjee B., Nydegger U. E., Mohacsi P. Serum erythropoietin in heart failure patients treated with ACE-inhibitors or AT(1) antagonists. Eur J Heart Fail. 2000 ; 2 (4) : 393–398. doi: 10.1016/s1388-9842(00)00110-0.</mixed-citation><mixed-citation xml:lang="en">Chatterjee B., Nydegger U. E., Mohacsi P. Serum erythropoietin in heart failure patients treated with ACE-inhibitors or AT(1) antagonists. Eur J Heart Fail. 2000 ; 2 (4) : 393–398. doi: 10.1016/s1388-9842(00)00110-0.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Girelli D., Marchi G., Camaschella C. Anemia in the Elderly. Hemasphere. 2018 ; 2 (3) : e40. doi: 10.1097/HS9.0000000000000040.</mixed-citation><mixed-citation xml:lang="en">Girelli D., Marchi G., Camaschella C. Anemia in the Elderly. Hemasphere. 2018 ; 2 (3) : e40. doi: 10.1097/HS9.0000000000000040.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Булгакова С. В., Захарова Н. О., Тренева Е. В., Лобинская М. А. Современные представления об анемическом синдроме у лиц старших возрастных групп (обзор литературы) // Современные проблемы здравоохранения и медицинской статистики. — 2020. — № 2. — С. 45–68.</mixed-citation><mixed-citation xml:lang="en">Bulgakova S. V., Zakharova N. O., Treneva E. V., Lobinskaya M. A. Current understanding of anemic syndrome in older age groups (literature review). Current problems of health care and medical statistics. 2020 ; (2) ; 45–68. (In Russ.). doi: 10.24411/2312-2935-2020-10031.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Belonje A. M., Voors A. A., van der Meer P., et al. Endogenous erythropoietin and outcome in heart failure. Circulation. 2010 ; 121 (2) :245–251. doi: 10.1161/CIRCULATIONAHA.108.844662.</mixed-citation><mixed-citation xml:lang="en">Belonje A. M., Voors A. A., van der Meer P., et al. Endogenous erythropoietin and outcome in heart failure. Circulation. 2010 ; 121 (2) : 245–251. doi: 10.1161/CIRCULATIONAHA.108.844662.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Opasich C., Cazzola M., Scelsi L., et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J. 2005 ; 26 (21) : 2232–2237. doi: 10.1093/eurheartj/ehi388.</mixed-citation><mixed-citation xml:lang="en">Opasich C., Cazzola M., Scelsi L., et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J. 2005 ; 26 (21) : 2232–2237. doi: 10.1093/eurheartj/ehi388.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">McDonagh T. A., Metra M., Adamo M., et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 ; 42 (36) : 3599–3726. doi: 10.1093/eurheartj/ehab368.</mixed-citation><mixed-citation xml:lang="en">McDonagh T. A., Metra M., Adamo M., et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 ; 42 (36) : 3599–3726. doi: 10.1093/eurheartj/ehab368.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Мареев В. Ю., Фомин И. В., Агеев Ф. Т. и др. Клинические рекомендации ОССН — РКО — РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. // Кардиология. — 2018. — Т. 58, № 6S. — С. 8–158.</mixed-citation><mixed-citation xml:lang="en">Mareev V. Y., Fomin I. V., Ageev F. T. et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologia. 2018 ; 58 (6S) : 8–158. (In Russ.). doi.org/10.18087/cardio.2475.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Гуркина А. А., Стуклов Н. И., Кислый Н. Д. и др. Характеристика анемии при хронической сердечной недостаточности: обмен железа, активность эритропоэза и маркеры воспаления // Кардиоваскулярная терапия и профилактика. — 2023 Т. 22, № 1. — С. 14–20.</mixed-citation><mixed-citation xml:lang="en">Gurkina A. A., Stuklov N. I., Kisly N. D., et al. Characteristics of anemia in heart failure: iron metabolism, erythropoietic activity and markers of inflammation. Cardiovascular Therapy and Prevention. 2023 ; 22 (1) : 3332 (In Russ.). doi: 10.15829/1728-8800-2023-3332.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Zahidova K. K. Indexes of the erythropoietin level in the blood plasma of chronic heart failure patients with anemia. J Basic Clin Physiol Pharmacol. 2018 ; 29 (1) : 11–17. doi: 10.1515/jbcpp-2016-0102.</mixed-citation><mixed-citation xml:lang="en">Zahidova K. K. Indexes of the erythropoietin level in the blood plasma of chronic heart failure patients with anemia. J Basic Clin Physiol Pharmacol. 2018 ; 29 (1) : 11–17. doi: 10.1515/jbcpp-2016-0102.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Макарова Н. А. Современные пути коррекции дефицита железа при хронической сердечной недостаточности. // Непрерывное медицинское образование и наука. — 2023 Т. 18, № 1. — С. 23–28.</mixed-citation><mixed-citation xml:lang="en">Makarova N. A. Present ways of iron deficiency correction in chronic heart failure. Nepreryvnoe medicinskoe obrazovanie i nauka. 2023 ; 18 (1) : 23–28. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Smith K. J., Bleyer A. J., Little W. C., Sane D. C. The cardiovascular effects of erythropoietin. Cardiovasc Res. 2003 ; 59 (3) : 538–548. doi: 10.1016/s0008-6363(03)00468-1.</mixed-citation><mixed-citation xml:lang="en">Smith K. J., Bleyer A. J., Little W. C., Sane D. C. The cardiovascular effects of erythropoietin. Cardiovasc Res. 2003 ; 59 (3) : 538–548. doi: 10.1016/s0008-6363(03)00468-1.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Markousis-Mavrogenis G., Tromp J., Ouwerkerk W., et al. The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study. Eur J Heart Fail. 2019 ; 21 (8) : 965–973. doi: 10.1002/ejhf.1482.</mixed-citation><mixed-citation xml:lang="en">Markousis-Mavrogenis G., Tromp J., Ouwerkerk W., et al. The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study. Eur J Heart Fail. 2019 ; 21 (8) : 965–973. doi: 10.1002/ejhf.1482.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Weiss G., Ganz T., of inflammation. Blood. 2019 ; 133 (1) : 40–50. doi: 10.1182/blood-2018-06-856500.</mixed-citation><mixed-citation xml:lang="en">Weiss G., Ganz T., of inflammation. Blood. 2019 ; 133 (1) : 40–50. doi: 10.1182/blood-2018-06-856500.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Лыков А. П. Эритропоэтин: функции и терапевтический потенциал // Сибирский ский журнал. — 2023. — Т. 43, № 3. — С. 29–39.</mixed-citation><mixed-citation xml:lang="en">Lykov A. P. Erythropoietin: function and therapeutic potential. Sibirskij nauchnyj medicinskij zhurnal = Siberian Scientific Medical Journal. 2023 ; 43 (3) : 29–39. (In Russ.). doi: 10.18699/SSMJ20230203.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Swedberg K., Young J. B., Anand I. S., et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med. 2013 ; 368 (13) : 1210–1219. doi: 10.1056/NEJMoa1214865.</mixed-citation><mixed-citation xml:lang="en">Swedberg K., Young J. B., Anand I. S., et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med. 2013 ; 368 (13) : 1210–1219. doi: 10.1056/NEJMoa1214865.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Docherty K. F., Welsh P., Verma S., et al. Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF. Circulation. 2022 ; 146 (13) : 980–994. doi: 10.1161/CIRCULATIONAHA.122.060511.</mixed-citation><mixed-citation xml:lang="en">Docherty K. F., Welsh P., Verma S., et al. Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF. Circulation. 2022 ; 146 (13) : 980–994. doi: 10.1161/CIRCULATIONAHA.122.060511.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Szczech L. A., Barnhart H. X., Inrig J. K., et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008 ; 74 (6) : 791–798. doi: 10.1038/ki.2008.295.</mixed-citation><mixed-citation xml:lang="en">Szczech L. A., Barnhart H. X., Inrig J. K., et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008 ; 74 (6) : 791–798. doi: 10.1038/ki.2008.295.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
